Lionco Pharmaceutical Group Co.,Ltd.

SHSE:603669 Stock Report

Market Cap: CN¥3.5b

Lionco Pharmaceutical GroupLtd Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Ling Ping Tao

Chief executive officer

CN¥660.0k

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership6.8%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Jan 02
Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Subdued Growth No Barrier To Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) With Shares Advancing 30%

Nov 06
Subdued Growth No Barrier To Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) With Shares Advancing 30%

Lionco Pharmaceutical GroupLtd (SHSE:603669) Has Debt But No Earnings; Should You Worry?

Oct 29
Lionco Pharmaceutical GroupLtd (SHSE:603669) Has Debt But No Earnings; Should You Worry?

Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

May 10
Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump

Mar 12
There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump

CEO

Ling Ping Tao (54 yo)

no data

Tenure

CN¥660,000

Compensation

Ms. Ling Ping Tao is General Manager of Lionco Pharmaceutical Group Co.,Ltd. and serves as its Chairman of the Board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 01:50
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lionco Pharmaceutical Group Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution